FDA Approved Spravato® Depression Medication

Anti-Depression Medication

Approved by the FDA in March 2019, Spravato® is a Ketamine-based anti-depressant promises quick relief from symptoms of depression.

Spravato “does something that very few things in psychiatry can do — it works for people who didn’t respond to other treatments, and it works fast,” says psychiatrist Dan Iosifescu of New York University’s School of Medicine. “I really welcome having another powerful tool in my toolbox.”

“There has been a long-standing need for additional effective treatments for treatment-resistant depression, a serious and life-threatening condition,” said Tiffany Farchione, M.D., acting director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research. “Controlled clinical trials that studied the safety and efficacy of this drug, along with careful review through the FDA’s drug approval process including a robust discussion with our external advisory committees, were important to our decision to approve this treatment.

Consult with your doctor to determine if Spravato® is right for you, and bring or call-in your prescription. Our experienced and friendly pharmacists are ready to answer any questions you may have.